Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -2.56% and Operating profit at -228.94% over the last 5 years
- The company is Net-Debt Free
2
Negative results in Mar 26
3
Risky -
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,938 Million (Small Cap)
NA (Loss Making)
NA
0.00%
1.54
-69.37%
3.11
Revenue and Profits:
Net Sales:
149 Million
(Quarterly Results - Jun 2026)
Net Profit:
-28 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.2%
0%
10.2%
6 Months
-6.63%
0%
-6.63%
1 Year
2.69%
0%
2.69%
2 Years
27.56%
0%
27.56%
3 Years
-15.73%
0%
-15.73%
4 Years
-7.43%
0%
-7.43%
5 Years
-20.78%
0%
-20.78%
Hubei Guangji Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.56%
EBIT Growth (5y)
-228.94%
EBIT to Interest (avg)
-1.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.74
Sales to Capital Employed (avg)
0.30
Tax Ratio
1.08%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.09%
ROE (avg)
2.78%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.07
EV to EBIT
-6.99
EV to EBITDA
-9.91
EV to Capital Employed
1.81
EV to Sales
4.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-25.95%
ROE (Latest)
-69.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
148.90
135.90
9.57%
Operating Profit (PBDIT) excl Other Income
11.20
12.20
-8.20%
Interest
10.10
16.50
-38.79%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-28.10
-42.10
33.25%
Operating Profit Margin (Excl OI)
-155.30%
-211.10%
5.58%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 9.57% vs 16.85% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 33.25% vs 30.87% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
621.10
623.20
-0.34%
Operating Profit (PBDIT) excl Other Income
5.70
-51.50
111.07%
Interest
51.60
62.40
-17.31%
Exceptional Items
-253.90
-27.90
-810.04%
Consolidate Net Profit
-438.90
-315.10
-39.29%
Operating Profit Margin (Excl OI)
-251.80%
-350.80%
9.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -0.34% vs -15.05% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -39.29% vs -106.76% in Dec 2024
About Hubei Guangji Pharmaceutical Co., Ltd. 
Hubei Guangji Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






